arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

HERON THERAPEUTICS, INC. /DE/

HRTX
$0.50 0.00 (-0.48%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

HERON THERAPEUTICS, INC. /DE/ faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $83.4M
Dividend Yield
Revenue Growth 7.4%
Op. Margin -1.6%
ROIC -14.0%
FCF / Share $-0.17
Trailing P/E
Price / Book 6.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$154.90M
↑ +7.4%
Net Income Profit after all expenses
$-20.20M
↓ -48.7%
Operating Margin Operating profit as % of sales
-1.6%
↑ +79.5% 25th
FCF / Share Free cash flow per share
$-0.17
↓ -5.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
16
Returns
5
Financial Health
47
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters